{"id":2305,"date":"2026-06-11T15:00:00","date_gmt":"2026-06-11T18:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2305"},"modified":"2026-06-11T15:00:00","modified_gmt":"2026-06-11T18:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-peniana-avancada-penectomia-ila-brachy-pembrolizumab-enfortumab-vedotin","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-peniana-avancada-penectomia-ila-brachy-pembrolizumab-enfortumab-vedotin\/","title":{"rendered":"PGRSS peniana avan: penec, ILA, EV, pembro"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica peniana avan\u00e7ada que reduzem PGRSS a descarte de bisturi e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica peniana avan\u00e7ada<\/strong> + CCP carcinoma escamoso peniano + verrucoso+sarcomatoide+adenoescamoso+adenoCa raro+melanoma peniano+sarcoma<\/strong> + HPV-driven 30-50% jovem+HPV-independent 50-70% lichen+inflama\u00e7\u00e3o cr\u00f4nica+balanitis xerotica obliterans+phimosis<\/strong> + penectomia parcial preservadora glansectomia+penectomia total+emascula\u00e7\u00e3o+Mohs surgery + skin grafting+VRAM<\/strong> + ILA Inguinal Lymphadenectomy bilateral+sentinela DSL Tc-99m+ICG+EAU recommendation<\/strong> + brachy intersticial Iridium-192 peniana CTV<\/strong> + pembrolizumab Keytruda HERCULES + cemiplimab Libtayo HPV-positive + enfortumab vedotin Padcev EV-103+EV-302 mUC overlap + nivolumab+ipilimumab CheckMate-358 + tisotumab vedotin Tivdak HPV-driven<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (CCP escamoso 95%+verrucoso+sarcomatoide+adenoescamoso+melanoma rar\u00edssimo+sarcoma+VIN\/PIN penile intraepithelial neoplasia high-grade) + Grupo A4 (ILA Inguinal Lymphadenectomy superficial+profunda+pelvic il\u00edaca interna externa+SLN sentinela DSL+linfedema membro inferior) + Grupo C (Iridium-192 brachy intersticial peniana+CTV+CNEN-NN-3.05) + Grupo E (perfuro bi\u00f3psia incisional+excisional+circuncis\u00e3o+Mohs micrographic surgery) + Lista C5 (cisplatina+5-FU TIP paclitaxel+ifosfamida+cisplatina + EAU TPF docetaxel+cisplatina+5-FU + pembrolizumab Keytruda Merck HERCULES + cemiplimab Libtayo Regeneron PD-1 EMPOWER-CSCC HPV+ + enfortumab vedotin Padcev Pfizer\/Astellas\/Seagen Nectin-4 ADC overlap urotelial+penile + tisotumab vedotin Tivdak InnovativeBio Pfizer ADC tissue factor TF HPV-driven + nivolumab Opdivo BMS CheckMate-358+ipilimumab Yervoy + atezolizumab Tecentriq + durvalumab Imfinzi + cemiplimab Libtayo Lista C5).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica peniana avan\u00e7ada, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos penianos avan\u00e7ados<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS peniana avan\u00e7ada tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 CCP escamoso+VIN<\/td>\n5-13 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nHPV+\/HPV-+CID C60<\/td>\n<\/tr>\n
A4 ILA+SLN DSL+pelvic<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nSentinela ICG+Tc-99m<\/td>\n<\/tr>\n
C brachy Iridium-192<\/td>\n0,5-1,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nCTV+CNEN<\/td>\n<\/tr>\n
E circuncis\u00e3o+Mohs<\/td>\n0,4-1,2 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nBi\u00f3psia+frozen section<\/td>\n<\/tr>\n
Lista C5 TIP+EAU+EV<\/td>\n1,5-4,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nHERCULES+Tivdak<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 11,4-32,2 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica peniana avan\u00e7ada m\u00e9dia porte.<\/p>\n

A1 CCP carcinoma escamoso + VIN\/PIN + HPV-driven vs HPV-independent: o est\u00e1gio cir\u00fargico<\/h2>\n

A primeira camada do PGRSS peniana avan\u00e7ada \u00e9 A1. Padr\u00e3o setorial inclui (a) CCP carcinoma escamoso peniano 95%<\/strong> com HPV-driven 30-50% jovem mais responsivo + HPV-independent 50-70% lichen+inflama\u00e7\u00e3o cr\u00f4nica+phimosis+balanitis xerotica obliterans BXO+higiene prec\u00e1ria; (b) outros tipos<\/strong> com verrucoso variant + sarcomatoide poor + adenoescamoso raro + melanoma peniano rar\u00edssimo 1% + sarcoma + leiomiossarcoma corpo cavernoso; (c) VIN\/PIN penile intraepithelial neoplasia<\/strong> com HSIL high-grade squamous + Bowen disease + erythroplasia Queyrat + Bowenoid papulose + carcinoma in situ CIS + HPV testing; (d) estadiamento TNM 8\u00aa edi\u00e7\u00e3o<\/strong> Tis+Ta+T1a\/T1b+T2a\/b+T3+T4+N0-N3+M0\/M1+CID C60 + EAU 2024 TNM specific recommendations + Heyns staging + Pizzocaro grade; (e) circuncis\u00e3o diagn\u00f3stica+terap\u00eautica<\/strong> com bi\u00f3psia 4mm punch + bi\u00f3psia incisional + excisional + Mohs micrographic surgery 5-mm slices frozen section + glansectomia.<\/p>\n

Cl\u00ednica com A1 CCP madura garante margem R0<\/strong> + previne recidiva regional<\/strong> + otimiza estadiamento TNM 8\u00aa+EAU 2024+HPV status<\/strong>. Como discutimos no post sobre peniana<\/a>, A1 peniana \u00e9 base.<\/p>\n

A4 penectomia parcial+total + ILA + SLN DSL + pelvic il\u00edaca: o est\u00e1gio cir\u00fargico<\/h2>\n

A segunda camada \u00e9 t\u00e9cnica. Padr\u00e3o setorial inclui (a) penectomia preservadora<\/strong> com glansectomia + skin grafting + Mohs micrographic surgery + cirurgia conservadora T1a low-risk + neouretroplastia perineal; (b) penectomia parcial+total<\/strong> com 2cm margem grossa + reconstru\u00e7\u00e3o perineal+escrotoplastia + emascula\u00e7\u00e3o T4 invas\u00e3o escrotal\/perineal + uretrostomia perineal; (c) ILA Inguinal Lymphadenectomy<\/strong> com superficial Daseler zones + profunda femoral + Cloquet + bilateral profil\u00e1tica T1G2-T4 + indica\u00e7\u00e3o cN0 + dynamic sentinel preferred + linfedema membro inferior 18-35% complica\u00e7\u00e3o; (d) SLN sentinela DSL Dynamic Sentinel Lymph Node biopsy<\/strong> com Tc-99m + ICG indocyanine green + Catalona protocol + EAU recommendation cN0 + ultrastaging IHC + omitir ILA completa SLN-negativo unifocal; (e) pelvic linfadenectomia il\u00edaca interna externa primitiva<\/strong> com indica\u00e7\u00e3o \u22652 LN inguinais positivos+extranodal extension + obturador + presacral + para-a\u00f3rtica at\u00e9 bifurca\u00e7\u00e3o + ePLND extended pelvic.<\/p>\n

Cl\u00ednica com A4 penectomia+ILA+SLN+pelvic madura escala R0 90+%<\/strong> + escala SLN DSL EAU recommendation omite ILA<\/strong> + previne linfedema 18-35% ILA completa<\/strong>. Conex\u00e3o com peniana<\/a>.<\/p>\n

Brachy Iridium-192 + TIP + EAU TPF + pembrolizumab HERCULES + EV+pembro EV-302 overlap + Tivdak HPV: o est\u00e1gio sist\u00eamico+ADC+imuno<\/h2>\n

A terceira camada \u00e9 brachy+sist\u00eamico+targeted. Padr\u00e3o setorial inclui (a) brachy intersticial Iridium-192 peniana<\/strong> com agulhas paralelas template + Pierquin + Fontanesi + LDR low dose rate + HDR high dose rate + after-loading remote + dosimetria 3D ICRU-58\/89 + CTV peniana CTV-HSIL EMBRACE-II adaptive + RT EBRT 50-60 Gy fra\u00e7\u00f5es 25-30; (b) TIP paclitaxel+ifosfamida+cisplatina<\/strong> + EAU TPF docetaxel+cisplatina+5-FU + cisplatina+5-FU cl\u00e1ssico + carbo+gemcitabina alternativa + neoadjuvante T3-T4 + adjuvante LN+ + induction; (c) pembrolizumab Keytruda Merck HERCULES<\/strong> PD-1 mUC mUC peniana overlap + KEYNOTE-A39 + cemiplimab Libtayo Regeneron PD-1 EMPOWER-CSCC HPV-positive cutaneous squamous cell + HPV-driven peniana cross-over recommendation; (d) enfortumab vedotin Padcev Pfizer\/Astellas\/Seagen Nectin-4 ADC<\/strong> EV-302 1L mUC OS 31,5m + EV-103 + overlap urotelial peniano comum biology + tisotumab vedotin Tivdak InnovativeBio Pfizer tissue factor TF ADC HPV-driven HPV+ peniana+vulvar+cervical innovaTV-204; (e) outras mol\u00e9culas<\/strong> nivolumab Opdivo BMS CheckMate-358 + ipilimumab Yervoy + atezolizumab Tecentriq + durvalumab Imfinzi + cemiplimab Libtayo + sotorasib KRAS raro + larotrectinib NTRK + sotorasib+adagrasib KRAS-G12C + selpercatinib RET Lista C5.<\/p>\n

Cl\u00ednica com brachy+TIP+pembro+EV+Tivdak madura escala brachy CTV-HSIL EMBRACE-II local control 80+%<\/strong> + escala HERCULES PD-1 mUC overlap<\/strong> + escala EV-302 OS 31,5m mUC overlap peniana<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade peniana avan\u00e7ada<\/h2>\n

Cl\u00ednica peniana avan s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 9.000-26.000<\/strong> mas perda de A4+brachy+E+sist\u00eamico.<\/p>\n

Cl\u00ednica peniana avan A1 + A4 + TIP.<\/strong> 3 fluxos. Custo mensal R$ 22.000-54.000<\/strong>, captura cirurgia + sist\u00eamico padr\u00e3o.<\/p>\n

Cl\u00ednica peniana avan 5 fluxos completos.<\/strong> A1+A4+brachy+E+sist\u00eamico + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 40.000-95.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura completa peniana avan\u00e7ada + HERCULES+Tivdak HPV-driven + EV-302 overlap mUC + SLN DSL EAU.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica peniana avan\u00e7ada<\/h2>\n

O primeiro \u00e9 a subdimensionamento Lista C5 imuno+ADC peniana<\/strong>. Sem segrega\u00e7\u00e3o cisplatina+paclitaxel+ifosfamida+5-FU+docetaxel+pembrolizumab+cemiplimab+enfortumab vedotin+tisotumab vedotin+nivolumab+ipilimumab+atezolizumab+durvalumab + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada profissional + impacto financeiro.<\/p>\n

O segundo \u00e9 a mistura A1 CCP escamoso + verrucoso + sarcomatoide + HPV-driven vs HPV-independent<\/strong>. Confunde rastreabilidade etiologia HPV + impossibilita TNM 8\u00aa+EAU 2024+Heyns+Pizzocaro + risco indica\u00e7\u00e3o inadequada (HPV+ pembro vs HPV- chemo vs Tivdak HPV-driven).<\/p>\n

O terceiro \u00e9 a falta de protocolo SLN DSL Catalona EAU recommendation cN0<\/strong>. Sem Tc-99m + ICG indocyanine green + Catalona protocol + dynamic sentinel + ultrastaging IHC + EAU recommendation = perda omite ILA completa + risco linfedema 18-35% ILA completa desnecess\u00e1ria.<\/p>\n

A regula\u00e7\u00e3o de PGRSS peniana avan\u00e7ada no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer P\u00eanis<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS peniana avan\u00e7ada 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 CCP carcinoma escamoso peniano 95%+HPV-driven 30-50% jovem+HPV-independent 50-70% lichen+phimosis+BXO balanitis xerotica obliterans+verrucoso+sarcomatoide+adenoescamoso+melanoma 1%+sarcoma+VIN\/PIN+Bowen disease+erythroplasia Queyrat+Bowenoid papulose+CIS+TNM 8\u00aa+EAU 2024+Heyns+Pizzocaro+CID C60, A4 penectomia preservadora glansectomia+Mohs micrographic surgery 5mm frozen section+skin grafting+penectomia parcial+total 2cm margem+emascula\u00e7\u00e3o+escrotoplastia+uretrostomia perineal+ILA Inguinal Lymphadenectomy superficial Daseler zones+profunda femoral+Cloquet+bilateral profil\u00e1tica T1G2-T4+SLN DSL Dynamic Sentinel Lymph Node Tc-99m+ICG+Catalona protocol+EAU recommendation cN0+ultrastaging IHC+pelvic il\u00edaca interna externa primitiva+obturador+presacral+ePLND extended+linfedema 18-35%, C brachy intersticial Iridium-192+template Pierquin+Fontanesi+LDR\/HDR+ICRU-58\/89+CTV-HSIL EMBRACE-II adaptive+EBRT 50-60 Gy 25-30 fra\u00e7\u00f5es+CNEN-NN-3.05, E circuncis\u00e3o+bi\u00f3psia 4mm punch+incisional+excisional+Mohs+frozen section+colposcopia peniana+\u00e1cido ac\u00e9tico+lugol Schiller, Lista C5 cisplatina+5-FU+TIP paclitaxel+ifosfamida+cisplatina+EAU TPF docetaxel+cisplatina+5-FU+carbo+gemcitabina+pembrolizumab Keytruda Merck HERCULES PD-1+KEYNOTE-A39+cemiplimab Libtayo Regeneron PD-1 EMPOWER-CSCC HPV+overlap+enfortumab vedotin Padcev Pfizer\/Astellas\/Seagen Nectin-4 ADC EV-302+EV-103 overlap mUC+tisotumab vedotin Tivdak InnovativeBio Pfizer tissue factor TF ADC HPV-driven innovaTV-204+nivolumab Opdivo BMS CheckMate-358+ipilimumab Yervoy+atezolizumab Tecentriq+durvalumab Imfinzi+sotorasib KRAS+larotrectinib NTRK+selpercatinib RET.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS peniana avan\u00e7ada: penec + ILA + brachy + pembro + EV. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2304,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2712,3143,2070,3142],"class_list":["post-2305","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cirurgia-oncologica","tag-ev","tag-pembrolizumab","tag-peniana-avancada"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2305"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2305\/revisions"}],"predecessor-version":[{"id":4375,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2305\/revisions\/4375"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2304"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}